

ASSESSING THE PUBLIC HEALTH IMPACT OF THE ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN VACCINE (RSVPreF3 OA) AMONG OLDER ADULTS IN THE UNITED STATES (US)

¹GSK, Wavre, Belgium; ²GSK, Philadelphia, PA, USA; ³CHESS in Health, Bonheiden, Belgium; ⁴RTI Health Solutions, Research Triangle Park, NC, USA







Months following vaccination

Dashed lines represent extrapolation beyond the median trial follow-up period of the first season in the AReSVi006 phase III clinical trial.

Q METHODS



Presenting author: Elizabeth La, liz.m.la@gsk.com

Supplementary details on methods available through QR-code scanning

Molnar D¹, La E², Verelst F¹, Curran D¹, Poston S², Van Bellinghen L-A³, Graham J⁴

- **RSV LRTD: 2.63%**
- RSV ARI: 5.36%

- To achieve this modeled public health impact in real-world practice, efforts will be needed to support RSV vaccination among older \checkmark adults (e.g., through patient and healthcare provider education on RSV disease and vaccines).





EPH45

Funding: GlaxoSmithKline Biologicals SA (GSK study identifier: VEO-000319); Acknowledgments: Business & Decision Life Sciences c/o GSK (writer: Sarah Fico); Jessica Pickett, Zinan Yi, Will Herring and Ilse Van Vlaenderen